# Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ee3ed09c-6580-489f-bb06-0e93f612d604

> FDA guidance document: Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry. Issue date: March 01, 2024. Get complete insights and analysis.

---

## Details

- Title: Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-01
- Last Changed: 2024-03-28
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-1051">FDA-2021-D-1051</a>

## Related Documents

- [Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/drug-drug-interaction-assessment-for-therapeutic-proteins-guidance-for-industry-guidance-for-industry/2a0a5163-7a5f-4b3c-9eef-d94d670b6733)
- [Benefit-Risk Assessment for New Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-assessment-for-new-drug-and-biological-products/90bf84f4-05cf-4617-b13d-bbb345349aed)
- [Population Pharmacokinetics:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/population-pharmacokinetics-guidance-for-industry/acd44982-2fd1-4119-a9f0-697ef34947f3)